Correction: Pharmacokinetic Characteristics of Long‑Acting Injectable Antipsychotics for Schizophrenia: An Overview

CNS Drugs. 2025 Jan;39(1):111-112. doi: 10.1007/s40263-024-01138-4.

Christoph U Correll^{1

2

3}, Edward Kim⁴, Jennifer Kern Sliwa⁴, Wayne Hamm⁵, Srihari Gopal⁶, Maju Mathews⁶, Raja Venkatasubramanian⁶, Stephen R Saklad^{7

8}

¹ Department of Psychiatry and Molecular Medicine, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY, USA.
² Division of Psychiatric Research, Zucker Hillside Hospital, Glen Oaks, NY, USA.
³ Department of Child and Adolescent Psychiatry, Charité Universitätsmedizin Berlin, Berlin, Germany.
⁴ Janssen Scientific Affairs, LLC, Titusville, NJ, USA.
⁵ Janssen Scientific Affairs, LLC, Spring Hill, TN, USA.
⁶ Janssen Research and Development, LLC, Titusville, NJ, USA.
⁷ College of Pharmacy, Pharmacotherapy Division, The University of Texas at Austin, 7703 Floyd Curl Drive, MC 6220, San Antonio, TX, 78229-3900, USA. Saklad@uthscsa.edu.
⁸ Long School of Medicine, Pharmacotherapy Education and Research Center, UT Health San Antonio, San Antonio, TX, 78229-3900, USA. Saklad@uthscsa.edu.

No abstract available

Publication types